Global Targeted Therapy Drugs for Cancer Market Strategic Research Report

Scope of the Report

The global Targeted Therapy Drugs for Cancer market size is predicted to grow from US$ 118,360 million in 2025 to US$ 191,441 million in 2032; it is expected to grow at a CAGR of 7.6% from 2026 to 2032.

In 2025, global Targeted Therapy Drugs for Cancer reached approximately 58.76 M Units, with an average global market price of around 2059 USD per Unit.

Targeted therapy drugs for cancer are anticancer medicines designed to specifically interfere with molecular targets—such as mutated genes, abnormal proteins, or dysregulated signaling pathways—that drive the growth, survival, or spread of cancer cells. These targets are typically involved in processes like cell proliferation, angiogenesis, DNA repair, or immune evasion, and are more active or uniquely altered in cancer cells compared with normal cells.

Unlike traditional chemotherapy, which broadly affects rapidly dividing cells, targeted cancer therapies act in a more precise and mechanism-driven manner, aiming to block cancer-specific biological processes while minimizing damage to healthy tissues. They include small-molecule drugs (often taken orally and acting inside cells) and biologic agents such as monoclonal antibodies (usually acting on cell-surface targets or extracellular ligands). Targeted therapies are commonly selected based on biomarker or genetic testing, making them a central component of precision oncology.

The upstream raw materials for Targeted Therapy Drugs for Cancer mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and excipients. Typical suppliers include Pfizer, Roche, Merck, and AstraZeneca. Downstream applications are primarily in oncology and rare disease treatments.

The single-line production capacity of Targeted Therapy Drugs for Cancer varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

Global key Targeted Therapy Drugs for Cancer players cover Roche, Novartis, Merck, Pfizer, AstraZeneca, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Targeted Therapy Drugs for Cancer market?

What factors are driving Targeted Therapy Drugs for Cancer market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Targeted Therapy Drugs for Cancer market opportunities vary by end market size?

How does Targeted Therapy Drugs for Cancer break out by Type, by Application?

This report presents a comprehensive overview of the global Targeted Therapy Drugs for Cancer market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Kinase Inhibitors
• ADCs
• Others

Segment by Administration Route

• Oral Drugs
• Injectable Drugs
• Others

Segment by Molecular Properties

• Small Molecule Drugs
• Antibody Drugs
• Others

Segment by Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Stomach Cancer
• Liver Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Targeted Therapy Drugs for Cancer market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Lung Cancer, Breast Cancer, Colorectal Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact